Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Dr. Reddy's Labs - Weak quarter; outlook intact - HDFC Securities

Posted On: 2021-07-28 17:22:30 (Time Zone: UTC)

Mr. Bansi Desai, CFA, HDFC Securities and Mr. Karan Vora, Institutional Research Analyst, HDFC Securities

Dr. Reddy's Q1 EBITDA/PAT missed our estimates by 16%/12% on account of muted trends in the US, PSAI and increased SG&A spends. We expect US business momentum to improve in the coming quarters, led by ramp-up in new launches (gVascepa, gKuvan). While the investments in R&D (biosimilars) and marketing spends on brands (India, EMs) have increased, they are likely to improve the longer-term growth visibility for key markets. The company is confident of achieving its long-term goal of 25% EBITDA margin (19% in Q1), led by ramp-up in the US, scale-up in API and operational efficiency. We cut our estimates by 9%/4% for FY22/23e to factor in the Q1 miss and lower gross margin. Our revised TP is INR5,210/sh. ADD.

Revenue in line, margin disappoints: Revenue, at INR49bn, grew by 11% YoY as strong growth in India (+69% YoY, low base, increase in sale of COVID drugs, price increase), EU (+12% YoY) and other EMs (+27% YoY) offset subdued performance in the US (-1% QoQ) and PSAI business (-12% YoY). EBITDA margin declined to ~19% (-612bps YoY, -342bps QoQ) on the back of lower gross margin (-380bps YoY, -142bps QoQ, price erosion, inventory provision, product mix) and increase in SG&A cost (+205bps YoY, +77bps QoQ, marketing spends, Wockhardt integration).

Muted performance in US and PSAI; growth visibility remains strong: The US revenue declined to USD235mn (-1% QoQ) as volume growth and new launches were offset by increased price erosion. We expect the ramp-up in new launches such as gVascepa and gKuvan to drive higher revenues in the coming quarters. The medium-term growth visibility remains strong with key products in the pipeline such as gCopaxone and gNuvaring awaiting approval. The PSAI business gross margin declined to 21.6% (-1,180bps YoY, - 1,010bps QoQ) due to lower prices/volumes and inventory stocking in the previous quarters. The management is confident of long-term growth prospects, given the order book visibility.

Key call highlights: (a) gVascepa: launched at the end of quarter, expects further ramp-up in the coming quarters; (b) India: locally manufactured Sputnik-V roll-out from Sept-Nov; investing in nutrition / OTC brands; (c) Filed 30 DMFs (two in the US) and 70 formulations globally in the quarter; d) WC rose by INR12bn on account of increase in inventory and receivables.

Maintain ADD, risks: We reduce our estimates by 9%/4% for FY22/23 to factor in the Q1 miss and lower gross margin and revise our TP to INR5,210. Our target price is based on SOTP of 23x FY23e EPS, NPV of INR384/sh for gRevlimid and INR89/sh for Sputnik-V. Key risks: delay in key approvals, higher price erosion, and lower-than-expected growth in EMs.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs. 4730.2 as compared to the previous close of Rs. 4844.35. The total number of shares traded during the day was 179933 in over 26940 trades.

The stock hit an intraday high of Rs. 4875.85 and intraday low of 4666.95. The net turnover during the day was Rs. 854308457.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Automobile Sector - Monthly Quick View - Aug'21 - Mixed Performance across Segments - Reliance Securities

Axis Securities initiating coverage on ICICI Securities

Company Update - Minda Corporation - Q1FY22 - ICICI Direct

Quant Pick - PVR Ltd - ICICI Direct

Quant Pick - ONGC - ICICI Direct

Peak in the headline wholesale inflation is behind us - WPI August 2021 - Acuité Ratings

Sansera Engineering - IPO - Strong Outlook with Steady Cash Flow - Reliance Securities

APL Apollo Tubes - Journey from a semi-commodity player to a branded one - HDFC Securities

Nazara Technologies Ltd - Upbeat in medium-term, Uncertain over Long-term - YES Securities

IPO Review - Sansera Engineering Ltd - ICICI Direct

Overall index is still 0.3% lower than the pre-pandemic levels - IIP July 2021

YES SECURITIES on Monthly General Insurance & Mutual Funds Data

India urban logistics spaces expected to cross 7 million sq. ft by 2022: JLL

Neogen Chemicals - Breaking into the next orbit with a bang - HDFC Securities

Gladiator Stocks - Bharti Airtel Ltd - ICICI Direct

Gladiator Stocks - V-Guard - ICICI Direct

Balkrishna Industries - Industry export growth accelerates - ICICI Securities

HDFC Life Insurance - Exide Life Acquisition - Maintain ADD - YES Securities

Gladiator Stocks - Grindwell Norton - ICICI Direct

Gladiator Stocks - Godrej Properties - ICICI Direct

Monthly Auto Volumes - August 2021 - ICICI Direct

Stock Tales - Easy Trip Planners - ICICI Direct

IPO Review - Vijaya Diagnostic Centre Ltd - ICICI Direct

AU Small Finance Bank - Attrition at top level remains key challenge; business momentum sustained in Jul/Aug'21 - ICICI Securities

Gladiator Stocks - State Bank of India - ICICI Direct

Gladiator Stocks - PNC Infratech - ICICI Direct

Vijaya Diagnostic Centre Ltd - IPO Note - YES Securities

Consumer Durables Sector - Lockdown mars performance yet again - Institutional Research Desk at HDFC Securities

75% of the employees today want to be in office at least once a week as compared to 52% in October 2020: JLL

Gladiator Stocks - Safari Industries - ICICI Direct

Gladiator Stocks - Interglobe Aviation - ICICI Direct

IPO Review - Ami Organics Ltd - ICICI Direct

Q1FY22 GDP - 31st Aug 2021 - Acuité Ratings & Research

Avanti Feeds - Higher input prices hurt margins - ICICI Securities

Company Update - Restructuring - Aarti Industries - ICICI Direct

Q1FY22 Company Update - MM Forgings - ICICI Direct

Company Update - Arvind Fashions - ICICI Direct

Zomato - Can margins and multiples surprise? - ICICI Securities

Ujjivan Small Finance Bank - Top management change and lumpy provisioning concern to weigh on valuation in near term - ICICI Securities

Bharat Dynamics - Guided missile systems to drive orderbook and profit growth - ICICI Securities

Economy - Continued accommodation necessary despite inflationary risks: MPC minutes - ICICI Securities

InterGlobe Aviation - Annual report analysis: Liquidity management remains the mainstay in anticipation of traffic recovery - ICICI Securities

General insurance - Health remains dominant growth driver; Strong all-round performance by Bajaj Allianz - ICICI Securities

Earnings Wrap Q1FY22: Resilient earnings, limited impact of second Covid wave - ICICI Direct

Fine Organic Industries Results Review - In-line performance - HDFC Securities

Power Plus Sector Update - July witnessed strong ~10% generation growth - HDFC Securities

Information Technology Sector Update - 'Hit Refresh' - HDFC Securities

Maintain ADD on JK Cement - Healthy performance - HDFC Securities

Maintain BUY on Star Cement - Margin recovers on pricing gain - HDFC Securities

Maintain BUY on Sadbhav Engineering - Long road to recovery - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020